Direct answer: sleeve or bypass if you have GERD?

If you already have moderate or severe GERD before bariatric surgery, Roux-en-Y gastric bypass is usually the safer long-term choice. Sleeve gastrectomy can worsen reflux or create new reflux because it increases pressure inside the stomach tube and can weaken the anti-reflux barrier.

A sleeve can still be reasonable for selected patients with mild reflux, no esophagitis, no Barrett’s esophagus, and no significant hiatal hernia, but only after endoscopy and full counseling.

My short rule is this:

• Mild reflux, normal endoscopy: sleeve may be reasonable.
• Daily PPI use, esophagitis, hiatal hernia, or Barrett’s: bypass is usually the better choice.
• Confirmed Barrett’s esophagus: I recommend bypass, not sleeve.

The 30-second summary

The sleeve gastrectomy is the most common bariatric procedure performed worldwide. It is also the procedure with the strongest long-term association with new or worsening acid reflux. The SLEEVEPASS 10-year randomized trial (JAMA Surgery, 2022) and the SM-BOSS 10-year follow-up (2025) both showed significantly higher rates of GERD, esophagitis, and need for conversion to bypass in sleeve patients compared to Roux-en-Y gastric bypass. The Qumseya 2021 meta-analysis in Gastrointestinal Endoscopy found Barrett’s esophagus in 11.6% of patients post-sleeve at 3+ years, even in patients without obvious symptoms. If you have GERD before surgery, this decision is not academic. Here is how I choose, honestly, in my practice.

Why this decision matters more than most surgical decisions

Most patients walk into my office assuming the sleeve is the obvious choice. It is shorter, less complex, has a lower complication rate, and is what most of their friends had. They have heard about the bypass being "more aggressive" and assume it is reserved for severe cases.

That framing is incomplete. The sleeve is an excellent procedure for the right patient. It is a worse procedure for the wrong one. The single most important variable that separates those two patients is reflux.

Acid reflux disease is not just heartburn after dinner. Chronic GERD damages the esophageal lining. The damage progresses through stages: esophagitis (inflammation), then intestinal metaplasia, then Barrett’s esophagus (precancerous change), then in some patients, esophageal adenocarcinoma. Esophageal adenocarcinoma is one of the most lethal cancers in adults, with a 5-year survival below 20%. The pathway from GERD to cancer takes 10 to 30 years, which is exactly the time horizon of a bariatric surgery decision.

This is why I spend more time on the reflux conversation than on almost any other pre-operative topic. The choice between sleeve and bypass affects your cancer risk over the rest of your life.

What actually happens to GERD after a gastric sleeve

The sleeve gastrectomy removes about 80% of the stomach, leaving a narrow tube along the lesser curvature. The anatomy of that tube creates a few mechanical issues for reflux.

First, the lower esophageal sphincter (LES) loses some of its anatomical support because the gastric fundus that helped anchor the angle of His is gone. Second, the high-pressure sleeve generates intragastric pressure that overcomes the LES more easily, especially when the sleeve is created too tightly. Third, if a hiatal hernia is missed and not repaired during the operation, the reflux barrier is compromised from the start.

Here is the timeline I see in my own patients.

First 3 months. New onset reflux is common in this window, often related to post-operative edema and not yet anatomic. PPIs (proton pump inhibitors) usually control symptoms. Most patients improve as edema resolves.

Months 4 through 12. As the sleeve matures and weight loss accelerates, reflux symptoms either resolve or persist. Patients who continue to have symptoms past month 6 are at higher risk of long-term GERD. We do an upper endoscopy at month 12 in any patient with persistent symptoms.

Years 1 through 10. This is where the trials matter. The SLEEVEPASS 10-year follow-up (240 patients randomized at trial start) found significantly higher prevalence of GERD symptoms and endoscopic esophagitis in the sleeve group compared to the bypass group. The SM-BOSS 10-year follow-up published in 2025 reported de novo GERD in 32.3% of sleeve patients versus 7.9% of bypass patients. Conversion rates from sleeve to another procedure (mostly bypass) were 29.9% versus 5.5%, primarily for inadequate weight loss or refractory reflux.

This is not a minor difference. Roughly 1 in 3 sleeve patients develop new reflux that did not exist before surgery, and about 1 in 4 eventually need a second operation. For comparison, the bypass group has stable reflux protection because the anatomy mechanically prevents acid from reaching the esophagus.

The Barrett’s esophagus question, honestly

The Qumseya 2021 meta-analysis in Gastrointestinal Endoscopy pooled 10 studies and 680 patients who had upper endoscopy 6 months to 10 years after sleeve gastrectomy. The pooled prevalence of Barrett’s esophagus was 11.6%. The rate of esophagitis increased by 13% annually post-operatively. Most cases of Barrett’s were detected after 3 years of follow-up. And critically: there was no consistent correlation between GERD symptoms and the presence of Barrett’s on endoscopy. Patients who felt fine still had it.

This is the data point that should make any surgeon pause. The relationship between post-sleeve symptoms and post-sleeve esophageal pathology is unreliable. We cannot tell who has Barrett’s without endoscopy. And Barrett’s, once established, requires surveillance every 3 to 5 years for the rest of the patient’s life.

For comparison, the bypass procedure has a very low rate of new Barrett’s because the anatomy fundamentally prevents the acid exposure that drives it.

So when a patient with mild reflux asks me "Will my GERD get worse with the sleeve?", my honest answer is: about a third of the time, yes. And we cannot reliably tell ahead of time who will be in that third.

When I recommend Roux-en-Y gastric bypass instead of sleeve

Based on the published trials and my own practice, I recommend the bypass over the sleeve when any of the following are present:

• Moderate-to-severe GERD requiring daily PPI before surgery
• Endoscopy showing esophagitis (any LA grade)
• Hiatal hernia larger than 2-3 cm
• Established Barrett’s esophagus (absolute indication for bypass)
• BMI above 50 (where the bypass tends to produce more durable weight loss)
• Type 2 diabetes with longer duration or insulin dependence (bypass has stronger metabolic effect)
• Patients who have already failed a sleeve at another center and are coming for revision

For these patients, the published 10-year evidence is clear. The bypass is the better operation, not just for weight loss but for the trajectory of their esophageal health over the next two to three decades.

When the sleeve is still a reasonable choice for a patient with mild GERD

The data does not say "never do a sleeve in a patient with GERD." It says "be careful, be technical, and screen long-term."

I will offer the Enhanced Gastric Sleeve to a patient with mild GERD when:

• No esophagitis on pre-op endoscopy
• No hiatal hernia, or a small one (under 2 cm) that we repair concurrently
• No Barrett’s esophagus
• Patient understands and accepts the long-term risk of worsening reflux and the surveillance commitment
• We agree on routine endoscopy at year 3 and year 5 post-op, even if asymptomatic
• The patient prefers the sleeve for personal reasons after full disclosure (recovery, simplicity, no malabsorption)

The Enhanced Gastric Sleeve in my practice includes specific technical modifications to reduce GERD risk: full hiatal dissection to identify any unsuspected hernia, primary repair (cruroplasty) of any hiatal defect found intraoperatively, preservation of the angle of His and the sling fibers of the LES, avoidance of overly tight sleeves at the incisura, and double buttress staple line reinforcement to minimize sleeve dilation over time.

These are not generic operative steps. They are intentional choices made because the long-term GERD data demands them.

The reflux-minded approach to the sleeve

When I say reflux-minded, I mean the operative philosophy treats the sleeve as a procedure with known long-term reflux risk and modifies the technique accordingly. The published data on technique-modified sleeves suggests reduced but not eliminated GERD risk.

The components I incorporate:

1. Full hiatal dissection on every case. Even when imaging shows no hernia, intraoperative dissection finds a small hernia in roughly 20-30% of patients. Repair them all.
2. Concurrent hiatoplasty when indicated. Posterior cruroplasty with non-absorbable suture, not staples.
3. Preserve the angle of His. The lateral attachments of the fundus support the LES. We dissect carefully to preserve these structures.
4. Avoid the tight incisura. The narrowing at the level of the incisura angularis is a known site of obstruction that drives reflux. Modern technique avoids it.
5. Double buttress the staple line. Reduces leak risk but also reduces long-term sleeve dilation, which is associated with worsening reflux.
6. Long-term endoscopic surveillance. Year 3 and Year 5 EGD even in asymptomatic patients. This is the only way to catch Barrett’s early.

What about Ozempic or Mounjaro for patients with GERD?

GLP-1 receptor agonists (semaglutide, tirzepatide) slow gastric emptying as part of their mechanism. This is helpful for satiety and glucose control. It is not helpful for reflux. Patients with pre-existing GERD often report symptom aggravation, particularly nocturnal reflux, while on these medications.

This does not contraindicate GLP-1 use, but it changes the conversation. For a patient with mild GERD and BMI 32 who is exploring medical management first, a GLP-1 may worsen their reflux. For a patient with severe GERD and BMI 42, bypass surgery is likely a better answer than either a GLP-1 or a sleeve.

Who should not have either bariatric procedure

Even with optimal procedure selection, some patients should not have surgery:

• Untreated severe esophagitis (LA grade C or D). Treat with PPIs and re-endoscope before considering surgery.
• Active eosinophilic esophagitis. Manage with gastroenterology first.
• Severe motility disorders (achalasia, jackhammer esophagus). Bypass is relatively contraindicated due to outlet anatomy.
• Active H. pylori infection. Eradicate before surgery.
• Severe gastroparesis. Both procedures may worsen symptoms.

These are not common, but they exist, and they are the reason pre-operative upper endoscopy is non-negotiable.

Quick answers

If I have GERD, should I get the sleeve or the bypass?
Mild GERD without esophagitis: sleeve with reflux-minded technique is reasonable. Moderate-to-severe GERD, esophagitis, hiatal hernia, or Barrett’s: bypass.

Can the sleeve cause new GERD?
Yes. SM-BOSS 10-year: 32.3% de novo GERD with sleeve vs 7.9% with bypass.

What is Barrett’s esophagus risk after sleeve?
Approximately 11.6% prevalence at 3+ years according to the Qumseya 2021 meta-analysis. No reliable correlation with symptoms.

Do I need endoscopy before surgery?
Yes. Mandatory. Identifies hiatal hernia, esophagitis, Barrett’s, H. pylori, and other issues that change procedure choice.

Can sleeve be converted to bypass if reflux worsens?
Yes. SM-BOSS 10-year: 29.9% sleeve patients required conversion. Technically feasible but a second operation.

Does bypass cure GERD?
In over 90% of patients, yes. Mechanically eliminates acid reflux.

Can I take PPIs forever?
You can, but long-term PPI use has real risks (osteoporosis, B12 deficiency, kidney effects). Symptom suppression is not the same as protection against Barrett’s progression.

If I have Barrett’s, can I still have bariatric surgery?
Yes, but Roux-en-Y gastric bypass only. Sleeve is contraindicated.

What to do next

If you have acid reflux and you are considering bariatric surgery, the first step is a virtual consultation. I will review your symptom history, your PPI use, any endoscopy results you have, and your overall metabolic picture. We will talk honestly about whether the sleeve makes sense for you or whether the bypass is the better long-term decision.

You can request a free virtual evaluation, and my coordinator Lucia will reach out to schedule. We move at your pace.

GERD is one of the few pre-operative variables that should change the procedure. Choosing the wrong operation for a patient with reflux can mean a second operation 5 years from now, or worse, a cancer surveillance program for life. The published 10-year data exists to help us make this decision correctly the first time.

For the complete picture of how bariatric surgery affects all major obesity-related conditions, including procedure-specific differences and honest comparisons with GLP-1 medications across each condition, see the comprehensive evidence guide.

Sources

1. Salminen P, Grönroos S, Helmiö M, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA Surg. 2022;157(8):656-666. PMID: 35731535
2. Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. JAMA. 2018;319(3):255-265. (10-year follow-up published 2025)
3. Qumseya BJ, Qumsiyeh Y, Ponniah SA, et al. Barrett’s esophagus after sleeve gastrectomy: a systematic review and meta-analysis. Gastrointest Endosc. 2021;93(2):343-352. PMID: 32798535
4. Sebastianelli L, Benois M, Vanbiervliet G, et al. Systematic Endoscopy 5 Years After Sleeve Gastrectomy Results in a High Rate of Barrett’s Esophagus: Results of a Multicenter Study. Obes Surg. 2019;29(5):1462-1469.
5. Long-term effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe obesity: a phase III multicentre randomised controlled trial (SleeveBypass). Lancet Regional Health Europe. 2024.
6. Risk of De Novo Barrett’s Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up. Clin Gastroenterol Hepatol. 2024.
7. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022;117(4):559-587.
8. Eisenberg D, Shikora SA, Aarts E, et al. 2022 ASMBS and IFSO: indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356.

---

Authored by Dr. Gabriela Rodríguez Ruiz, MD, PhD, FACS. Based on the SLEEVEPASS 10-year results (JAMA Surgery 2022), the SM-BOSS 10-year follow-up (2025), the Qumseya 2021 meta-analysis on Barrett’s esophagus after sleeve gastrectomy, and the 2024 SleeveBypass multicentre randomised controlled trial published in The Lancet Regional Health Europe.